Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 6/20 | 0.33 |
| ▸ | HHAT | Q5VTY9 | 3/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12044372 | 0.92 | TRPM8 (0.36) | LHCGRTRPM8NPC1SPRHHAT | |
| SCHEMBL12044376 | 0.84 | HCRTR1 (0.33) | SPR | |
| SCHEMBL7907305 | 0.83 | MAPK1 (0.37) | TRPM8NPC1SPRCYP2C19 | |
| SCHEMBL7908858 | 0.81 | SPR (0.44) | NPC1SPRCYP2C19 | |
| SCHEMBL7910744 | 0.78 | ALDH1A1 (0.37) | NPC1SPRCYP2C19 | |
| SCHEMBL1723486 | 0.77 | TRPM8 (0.35) | TRPM8SPR | |
| SCHEMBL10186505 | 0.76 | BCL2 (0.39) | — | |
| SCHEMBL12045103 | 0.76 | TRPM8 (0.36) | TRPM8SPR | |
| SCHEMBL7905582 | 0.76 | P2RX7 (0.43) | NPC1SPR | |
| SCHEMBL7907134 | 0.76 | MYC (0.40) | NPC1SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085134-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085134-A1 | QUINOXALINE COMPOUND | PDE9A, PDE2A, PDE3A | LHCGR 3723/4885TRPM8 1572/4885NPC1 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.